7 results on '"Biragyn, Arya"'
Search Results
2. Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging.
- Author
-
Biragyn, Arya and Ferrucci, Luigi
- Abstract
Cancer incidence substantially increases with ageing in both men and women, although the reason for this increase is unknown. In this Series paper, we propose that age-associated changes in gut commensal microbes, otherwise known as the microbiota, facilitate cancer development and growth by compromising immune fitness. Ageing is associated with a reduction in the beneficial commensal microbes, which control the expansion of pathogenic commensals and maintain the integrity of the intestinal barrier through the production of mucus and lipid metabolites, such as short-chain fatty acids. Expansion of gut dysbiosis and leakage of microbial products contributes to the chronic proinflammatory state (inflammaging), which negatively affects the immune system and impairs the removal of mutant and senescent cells, thereby enabling tumour outgrowth. Studies in animal models and the importance of commensals in cancer immunotherapy suggest that this status can be reversible. Thus, interventions that alter the composition of the gut microbiota might reduce inflammaging and rejuvenate immune functions to provide anticancer benefits in frail elderly people. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Mammalian defensins in immunity: more than just microbicidal
- Author
-
Yang, De, Biragyn, Arya, Kwak, Larry W., and Oppenheim, Joost J.
- Subjects
- *
PEPTIDE antibiotics , *ANTIBIOTICS , *IMMUNITY - Abstract
Mammalian defensins are small, cationic, antimicrobial peptides encoded by the host that are considered to be important antibiotic-like effectors of innate immunity. By using chemokine receptors on dendritic cells and T cells, defensins might also contribute to the regulation of host adaptive immunity against microbial invasion. Defensins have considerable immunological adjuvant activity and linkage of β-defensins or selected chemokines to an idiotypic lymphoma antigen has yielded potent antitumor vaccines. The functional overlap between defensins and chemokines is reinforced by reports that some chemokines have antimicrobial activities. Although showing similarity in activity and overall tertiary structure, the evolutionary relationship between defensins and chemokines remains to be determined. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
4. Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model
- Author
-
Cervantes-Villagrana, Alberto R., Hernández-Pando, Rogelio, Biragyn, Arya, Castañeda-Delgado, Julio, Bodogai, Monica, Martínez-Fierro, Margarita, Sada, Eduardo, Trujillo, Valentin, Enciso-Moreno, Antonio, and Rivas-Santiago, Bruno
- Subjects
- *
BCG vaccines , *DNA vaccines , *DEFENSINS , *MYCOBACTERIAL diseases , *ANTIGENS , *TUBERCULOSIS vaccines , *BIOLOGY experiments - Abstract
Abstract: The World Health Organization (WHO) has estimated that there are about 8 million new cases annually of active Tuberculosis (TB). Despite its irregular effectiveness (0–89%), the Bacillus Calmette-Guérin) BCG is the only vaccine available worldwide for prevention of TB; thus, the design is important of novel and more efficient vaccination strategies. Considering that β-defensin-2 is an antimicrobial peptide that induces dendritic cell maturation through the TLR-4 receptor and that both ESAT-6 and Ag85B are immunodominant mycobacterial antigens and efficient activators of the protective immune response, we constructed two DNA vaccines by the fusion of the gene encoding β-defensin-2 and antigens ESAT6 (pDE) and 85B (pDA). After confirming efficient local antigen expression that induced high and stable Interferon gamma (IFN-γ) production in intramuscular (i.m.) vaccinated Balb/c mice, groups of mice were vaccinated with DNA vaccines in a prime-boost regimen with BCG and with BCG alone, and 2 months later were challenged with the mild virulence reference strain H37Rv and the highly virulent clinical isolate LAM 5186. The level of protection was evaluated by survival, lung bacilli burdens, and extension of tissue damage (pneumonia). Vaccination with both DNA vaccines showed similar protection to that of BCG. After the challenge with the highly virulent Mycobacterium tuberculosis strain, animals that were prime-boosted with BCG and then boosted with both DNA vaccines showed significant higher survival and less tissue damage than mice vaccinated only with BCG. These results suggest that improvement of BCG vaccination, such as the prime-boost DNA vaccine, represents a more efficient vaccination scheme against TB. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. Induction of an effective anti-Amyloid-β humoral response in aged mice.
- Author
-
Illouz, Tomer, Madar, Ravit, Hirsh, Tamir, Biragyn, Arya, and Okun, Eitan
- Subjects
- *
HEPATITIS associated antigen , *IMMUNOSENESCENCE , *LABORATORY mice , *HEPATITIS B vaccines , *ALZHEIMER'S disease - Abstract
• Aged mice exhibit reduced production of anti-Amyloid-β antibodies following vaccination. • Priming with a xenogenic vaccine carrier enhances anti-Amyloid-β humoral response. • A xeno-prime-boost vaccine strategy reduces cerebral Amyloid-β levels. • This strategy alters microglial phenotype in an Alzheimer's disease mouse model. Aging-related decline in immune functions, termed immunosenescence, is a primary cause of reduced protective responses to vaccines in the elderly, due to impaired induction of cellular and humoral responses to new antigens (Ag), especially if the response is T cell dependent. The result is a more severe morbidity following infections, more prolonged and frequent hospitalization, and a higher mortality rate than in the general population. Therefore, there is an increasing need to develop vaccination strategies that overcome immunosenescence, especially for aging-related diseases such as Alzheimer's disease (AD). Here we report a new vaccination strategy harnessing memory-based immunity, which is less affected by aging. We found that aged C57BL/6 and 5xFAD mice exhibit a dramatic reduction in anti-Amyloid-β (Aβ) antibody (Ab) production. We aimed to reverse this process by inducing memory response at a young age. To this end, young mice were primed with the vaccine carrier Hepatitis B surface antigen (HBsAg). At an advanced age, these mice were immunized with an Aβ 1-11 fused to HBsAg. This vaccination scheme elicited a markedly higher Aβ-specific antibody titer than vaccinating aged unprimed mice with the same construct. Importantly, this vaccine strategy more efficiently reduced cerebral Aβ levels and altered microglial phenotype. Overall, we provide evidence that priming with an exogenous Ag carrier can overcome impaired humoral responses to self-antigens in the elderly, paving the route for a potent immunotherapy to AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease
- Author
-
Olkhanud, Purevdorj B., Mughal, Mohammed, Ayukawa, Koichi, Malchinkhuu, Enkhzol, Bodogai, Monica, Feldman, Neil, Rothman, Sarah, Lee, Jong-Hwan, Chigurupati, Srinivasulu, Okun, Eitan, Nagashima, Kunio, Mattson, Mark P., and Biragyn, Arya
- Subjects
- *
ALZHEIMER'S disease vaccines , *DISEASE progression , *IMMUNIZATION , *GENE expression , *B cells , *DNA vaccines , *EPITOPES , *TARGETED drug delivery , *LABORATORY mice - Abstract
Abstract: Alzheimer''s disease (AD) is an incurable and progressive neurodegenerative senile disorder associated with the brain accumulation of Aβ plaques. Although vaccines that reduce Aβ plaques can control AD, the rationale for their use at the onset of the disease remains debatable. Old humans and mice usually respond poorly to vaccines due to presumably age-related immunological impairments. Here, we report that by modifying vaccines, the poor responsiveness of old mice can be reversed. Unlike the Aβ peptide vaccine, DNA immunizations with the amino-terminal Aβ(1–11) fragment exposed on the surface of HBsAg particles elicit high levels of anti-Aβ antibody both in young and old mice. Importantly, in AD model 3xTgAD mice, the vaccine reduced Aβ plaques, ameliorated cognitive impairments and, surprisingly, significantly increased life span. Hence, we propose that vaccines targeting Aβ(1–11) can efficiently combat AD-induced pathological alterations and provide survival benefit in patients with AD. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
7. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera
- Author
-
Cha, Soung-Chul, Kwak, Larry W., Ruffini, Pier Adelchi, Qin, Hong, Neelapu, Sattva, and Biragyn, Arya
- Subjects
- *
ANTIGENS , *CHROMATOGRAPHIC analysis , *GENETIC engineering , *IMMUNOGLOBULINS - Abstract
Abstract: Active immunization of follicular lymphoma patients with idiotypic vaccines elicits antigen-specific antibody responses, T-cell responses, and antitumor effects. We hypothesized that these vaccinated patients could generate tumor-specific immune responses, not only against idiotype, but also against other tumor-associated antigens (TAA) by a mechanism of epitope spreading. To identify potential antigens, a phage surface expressed cDNA library derived from primary tumor cells was screened with sera from idiotype-vaccinated patients. Consistent with our hypothesis, we identified two immunogenic peptides (FL-aa-7 and 18), unrelated to idiotype, which were recognized by postvaccine sera but not by prevaccine or normal human sera. These peptide sequences derived from the 5′-untranslated regions of the human GTPase, IMAP family member 7 gene (FL-aa-7) and an alternative reading frame of U1-snRNP 70 (FL-aa-18), respectively, suggesting that epitope spreading had occurred. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.